HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia.

AbstractBACKGROUND:
A prior phase I/IIa clinical trial provided evidence for safety, feasibility and potential efficacy of i.m. injection of granulocyte colony-stimulating factor (G-CSF)-mobilized CD34+ cells in patients with critical limb ischemia (CLI).
METHODS AND RESULTS:
A phase II trial of CD34+ cell therapy was conducted in patients with CLI to explore endpoint selection and timing. No-option CLI patients (n=11) underwent i.m. transplantation of G-CSF-mobilized CD34+ cells isolated by magnetic sorting. Ischemic rest pain scales improved from week 2 vs. baseline (P<0.05). Skin perfusion pressure (P=0.0175), transcutaneous partial oxygen pressure (P=0.0446) and pain-free walking distance (P=0.0056) improved from week 2, total walking distance from week 8 (P=0.0182) and toe brachial pressure index from week 12 (P=0.0174) vs. baseline. These parameters peaked at week 36 or 52. Rutherford's category improved from week 24 vs. baseline (P=0.0065). CLI-free ratio serially increased and peaked (85.7%) at week 36. Serial change in Rutherford's category correlated with that in Rest Pain Scale (P=0.0374), but not with that in any physiological parameters.
CONCLUSIONS:
Ischemic rest pain scales and physiological parameters improved relatively early after cell therapy, then plateaued later accompanied by recovery from the CLI state. Rutherford's category and CLI-free ratio at week 36 or later may be suitable endpoints in cell therapy clinical trials for CLI. Functional parameters should be evaluated independently of such clinical endpoints for ischemia severity.
CLINICAL TRIAL REGISTRATION:
URL: https://dbcentre3.jmacct.med.or.jp/jmactr/Default.aspx. Unique identifier: JMA-IIA00022)  
AuthorsYasuyuki Fujita, Makoto Kinoshita, Yutaka Furukawa, Tohru Nagano, Hisako Hashimoto, Yasuhiko Hirami, Yasuo Kurimoto, Kyosuke Arakawa, Kazuo Yamazaki, Yukikatsu Okada, Nobuyuki Katakami, Emiko Uno, Yoshihiro Matsubara, Masanori Fukushima, Adel Nada, Douglas W Losordo, Takayuki Asahara, Yutaka Okita, Atsuhiko Kawamoto
JournalCirculation journal : official journal of the Japanese Circulation Society (Circ J) Vol. 78 Issue 2 Pg. 490-501 ( 2014) ISSN: 1347-4820 [Electronic] Japan
PMID24257136 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD34
Topics
  • Adult
  • Aged
  • Antigens, CD34
  • Autografts
  • Cell- and Tissue-Based Therapy (methods)
  • Female
  • Humans
  • Ischemia (physiopathology, therapy)
  • Lower Extremity (blood supply, physiopathology)
  • Male
  • Middle Aged
  • Pain (physiopathology)
  • Pain Management
  • Stem Cell Transplantation
  • Stem Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: